crispr
therapeutics
provides
business
update
reports
third
quarter
financial
results
positive
results
company
ongoing
phase
carbon
trial
evaluating
safety
efficacy
targeting
received
rare
pediatric
disease
designation
food
drug
administration
fda
sickle
cell
disease
scd
beta
thalassemia
tdt
orphan
drug
designation
odd
phase
clinical
trial
targeting
maturation
antigen
bcma
treating
patients
two
phase
clinical
trials
targeting
treatment
solid
tumors
certain
hematologic
zug
switzerland
cambridge
globe
newswire
crispr
therapeutics
nasdaq
crsp
biopharmaceutical
company
focused
creating
transformative
medicines
serious
diseases
today
reported
financial
results
third
quarter
ended
september
nobel
prize
chemistry
provides
timely
recognition
groundbreaking
potential
crispr
team
crispr
therapeutics
continues
make
important
progress
hemoglobinopathies
clinical
trials
earlier
month
pleased
report
positive
data
phase
carbon
trial
patients
relapsed
refractory
malignancies
demonstrate
potential
crispr
gene
editing
treatment
cancers
enrollment
trials
continue
expect
report
initial
data
programs
next
year
said
samarth
kulkarni
chief
executive
officer
crispr
therapeutics
parallel
clinical
trials
hemoglobinopathies
continue
advance
rapidly
expect
report
additional
data
program
later
recent
highlights
outlook
beta
thalassemia
sickle
cell
disease
crispr
therapeutics
vertex
previously
announced
june
seven
patients
dosed
across
two
phase
studies
investigational
crispr
therapy
presented
data
european
hematology
association
congress
two
tdt
patients
one
scd
patient
additional
patients
enrolled
dosed
tdt
scd
studies
company
expects
report
clinical
data
patients
treated
addition
data
patients
longer
fourth
quarter
european
medicines
agency
granted
priority
medicines
prime
designation
treatment
severe
scd
also
granted
regenerative
medicine
advanced
therapy
rmat
fast
track
orphan
drug
rare
pediatric
disease
designations
fda
odd
european
commission
tdt
scd
october
crispr
therapeutics
announced
positive
results
ongoing
phase
carbon
trial
evaluating
safety
efficacy
allogeneic
investigative
therapy
targeting
malignancies
data
showed
early
evidence
dose
dependent
response
demonstrated
complete
response
cr
rate
acceptable
safety
profile
responders
remained
cr
assessment
company
expects
report
additional
data
trial
crispr
therapeutics
received
odd
fda
company
allogeneic
investigative
therapy
targeting
bcma
treatment
relapsed
refractory
multiple
myeloma
crispr
therapeutics
continues
enroll
dose
patients
phase
clinical
trial
assessing
safety
efficacy
company
expects
report
data
trial
crispr
therapeutics
continues
enroll
dose
patients
two
independent
phase
clinical
trials
assessing
safety
efficacy
company
allogeneic
investigative
therapy
targeting
treatment
solid
tumors
certain
hematologic
malignancies
company
expects
report
data
trial
regenerative
medicine
crispr
therapeutics
together
partner
viacyte
planning
initiate
phase
trial
allogeneic
stem
therapy
treatment
type
diabetes
crispr
therapeutics
viacyte
entered
strategic
collaboration
focused
development
commercialization
novel
regenerative
medicines
including
allogeneic
stem
therapies
treatment
diabetes
combination
viacyte
stem
cell
capabilities
crispr
gene
editing
capabilities
potential
enable
replacement
product
may
deliver
durable
benefit
patients
without
requiring
immune
suppression
corporate
matters
october
professor
emmanuelle
charpentier
crispr
therapeutics
awarded
nobel
prize
chemistry
groundbreaking
work
crispr
system
founding
scientific
managing
director
max
planck
unit
science
pathogens
honorary
professor
humboldt
university
berlin
germany
third
quarter
financial
results
cash
position
cash
cash
equivalents
marketable
securities
billion
september
compared
million
june
increase
million
increase
cash
primarily
driven
july
public
offering
resulted
net
proceeds
approximately
million
offset
cash
used
operations
support
spending
company
clinical
programs
well
payroll
expenses
support
growth
cash
cash
equivalents
marketable
securities
billion
september
compared
million
june
increase
million
increase
cash
primarily
driven
july
public
offering
resulted
net
proceeds
approximately
million
offset
cash
used
operations
support
spending
company
clinical
programs
well
payroll
expenses
support
growth
revenue
total
collaboration
revenue
million
third
quarter
compared
million
third
quarter
resulted
collaboration
agreements
vertex
effective
third
quarter
total
collaboration
revenue
million
third
quarter
compared
million
third
quarter
resulted
collaboration
agreements
vertex
effective
third
quarter
r
expenses
r
expenses
million
third
quarter
compared
million
third
quarter
increase
expenses
driven
increased
headcount
supporting
facilities
related
expenses
well
development
activities
supporting
advancement
hemoglobinopathies
program
programs
r
expenses
million
third
quarter
compared
million
third
quarter
increase
expenses
driven
increased
headcount
supporting
facilities
related
expenses
well
development
activities
supporting
advancement
hemoglobinopathies
program
programs
g
expenses
general
administrative
expenses
million
third
quarter
compared
million
third
quarter
increase
general
administrative
expenses
year
driven
expense
general
administrative
expenses
million
third
quarter
compared
million
third
quarter
increase
general
administrative
expenses
year
driven
expense
net
loss
net
loss
million
third
quarter
compared
net
income
million
third
quarter
investigational
autologous
ex
vivo
crispr
therapy
evaluated
patients
suffering
tdt
severe
scd
patient
hematopoietic
stem
cells
engineered
produce
high
levels
fetal
hemoglobin
hbf
hemoglobin
f
red
blood
cells
hbf
form
hemoglobin
naturally
present
birth
switches
adult
form
hemoglobin
elevation
hbf
potential
alleviate
transfusion
requirements
tdt
patients
reduce
painful
debilitating
sickle
crises
scd
patients
based
progress
program
date
granted
regenerative
medicine
advanced
therapy
rmat
fast
track
orphan
drug
rare
pediatric
disease
designations
food
drug
administration
fda
also
granted
orphan
drug
designation
european
commission
tdt
scd
well
priority
medicines
prime
designation
european
medicines
agency
ema
scd
developed
agreement
crispr
therapeutics
vertex
among
approaches
investigated
evaluated
tdt
scd
furthest
advanced
clinical
development
ongoing
phase
trial
designed
assess
safety
efficacy
single
dose
patients
ages
tdt
trial
enroll
patients
follow
patients
approximately
two
years
infusion
patient
asked
participate
trial
ongoing
phase
trial
designed
assess
safety
efficacy
single
dose
patients
ages
severe
scd
trial
enroll
patients
follow
patients
approximately
two
years
infusion
patient
asked
participate
trial
wholly
owned
program
crispr
therapeutics
healthy
allogeneic
investigative
therapy
targeting
cluster
differentiation
investigated
carbon
trial
carbon
ongoing
phase
open
label
clinical
trial
carbon
designed
assess
safety
efficacy
several
dose
levels
treatment
relapsed
refractory
malignancies
asset
crispr
therapeutics
healthy
allogeneic
investigative
therapy
targeting
maturation
antigen
bcma
investigated
ongoing
phase
clinical
trial
designed
assess
safety
efficacy
several
dose
levels
treatment
relapsed
refractory
multiple
myeloma
based
progress
date
program
targeting
maturation
antigen
bcma
granted
orphan
drug
designation
fda
asset
crispr
therapeutics
healthy
allogeneic
investigative
therapy
targeting
cluster
differentiation
antigen
expressed
various
solid
tumors
hematologic
malignancies
developed
treatment
solid
tumors
renal
cell
carcinoma
hematologic
malignancies
investigated
two
ongoing
independent
phase
clinical
trials
designed
assess
safety
efficacy
several
dose
levels
treatment
relapsed
refractory
renal
cell
carcinoma
various
subtypes
lymphoma
respectively
crispr
therapeutics
crispr
therapeutics
leading
gene
editing
company
focused
developing
transformative
medicines
serious
diseases
using
proprietary
crispr
platform
crispr
revolutionary
gene
editing
technology
allows
precise
directed
changes
genomic
dna
crispr
therapeutics
established
portfolio
therapeutic
programs
across
broad
range
disease
areas
including
hemoglobinopathies
oncology
regenerative
medicine
rare
diseases
accelerate
expand
efforts
crispr
therapeutics
established
strategic
partnerships
leading
companies
including
bayer
vertex
pharmaceuticals
viacyte
crispr
therapeutics
ag
headquartered
zug
switzerland
subsidiary
crispr
therapeutics
r
operations
based
cambridge
massachusetts
business
offices
san
francisco
california
london
united
kingdom
information
please
visit
crispr
statement
press
release
may
contain
number
statements
within
meaning
private
securities
litigation
reform
act
amended
including
statements
made
kulkarni
press
release
well
statements
regarding
crispr
therapeutics
expectations
following
safety
efficacy
clinical
progress
crispr
therapeutics
various
clinical
programs
ii
status
clinical
trials
including
without
limitation
expectations
regarding
data
presented
expected
timing
data
releases
development
iii
data
generated
ongoing
planned
clinical
trials
ability
use
data
design
initiation
clinical
trials
including
expectations
regarding
data
recently
presented
iv
actual
potential
benefits
regulatory
designations
v
intellectual
property
coverage
positions
crispr
therapeutics
licensors
third
parties
well
status
potential
outcome
proceedings
involving
intellectual
property
vi
sufficiency
crispr
therapeutics
cash
resources
vii
expected
benefits
crispr
therapeutics
collaborations
viii
therapeutic
value
development
commercial
potential
crispr
gene
editing
technologies
therapies
without
limiting
foregoing
words
believes
anticipates
plans
expects
similar
expressions
intended
identify
statements
cautioned
statements
inherently
uncertain
although
crispr
therapeutics
believes
statements
based
reasonable
assumptions
within
bounds
knowledge
business
operations
statements
neither
promises
guarantees
necessarily
subject
high
degree
uncertainty
risk
actual
performance
results
may
differ
materially
projected
suggested
statements
due
various
risks
uncertainties
risks
uncertainties
include
among
others
potential
initial
preliminary
data
clinical
trial
initial
data
limited
number
patients
indicative
final
trial
results
potential
clinical
trial
results
may
favorable
one
crispr
therapeutics
internal
external
product
candidate
programs
proceed
planned
technical
scientific
commercial
reasons
future
competitive
market
factors
may
adversely
affect
commercial
potential
crispr
therapeutics
product
candidates
uncertainties
inherent
initiation
completion
preclinical
studies
crispr
therapeutics
product
candidates
including
without
limitation
availability
timing
results
whether
results
predictive
future
results
future
trials
uncertainties
regulatory
approvals
conduct
trials
market
products
potential
impacts
due
coronavirus
pandemic
x
delays
regulatory
review
manufacturing
supply
chain
interruptions
adverse
effects
healthcare
systems
disruption
global
economy
timing
progress
clinical
trials
preclinical
studies
research
development
activities
z
overall
impact
coronavirus
pandemic
business
financial
condition
results
operations
uncertainties
regarding
intellectual
property
protection
crispr
therapeutics
technology
intellectual
property
belonging
third
parties
outcome
proceedings
interference
opposition
similar
proceeding
involving
portion
intellectual
property
risks
uncertainties
described
heading
risk
factors
crispr
therapeutics
recent
annual
report
form
quarterly
report
form
subsequent
filings
made
crispr
therapeutics
securities
exchange
commission
available
sec
website
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
made
crispr
therapeutics
disclaims
obligation
undertaking
update
revise
statements
contained
press
release
extent
required
law
crispr
word
mark
design
logo
trademarks
registered
trademarks
crispr
therapeutics
ag
trademarks
registered
trademarks
property
respective
owners
crispr
therapeutics
ag
condensed
consolidated
statements
operations
unaudited
thousands
except
share
data
per
share
data
three
months
ended
september
nine
months
ended
september
collaboration
revenue
operating
expenses
research
development
general
administrative
total
operating
expenses
income
loss
operations
total
income
expense
net
net
income
loss
income
taxes
provision
income
taxes
net
income
loss
foreign
currency
translation
adjustment
unrealized
loss
marketable
securities
comprehensive
income
loss
net
income
loss
per
common
share
basic
basic
common
shares
outstanding
net
income
loss
per
common
share
diluted
diluted
common
shares
outstanding
crispr
therapeutics
ag
condensed
consolidated
balance
sheets
data
unaudited
thousands
september
december
cash
marketable
securities
working
capital
total
assets
total
shareholders
equity
investor
contact
susan
kim
media
contact
rachel
eides
wcg
behalf
crispr
reides
